シノバク・バイオテク | 6-K:海外発行者報告書(決算情報)
Sinovac Biotech 1H Loss/Shr $0.11 >SVA
国金证券:关注医药行业两个方向的投资机会
北京科兴生物制品有限公司申请III类会议
北京科兴生物制品有限公司申请II类会议
中國科興計劃今年起在巴西投資1億美元合作疫苗研發等
广发证券:1-4月医疗IT订单量额齐升,行业集中度有望提升
科兴生物制药股份有限公司申请II类会议
科兴生物制药因提供劳务者受害责任纠纷被告,6月26日在章丘市人民法院审理
Sinovac Biotech 2H Sales $307.9 >SVA
Seasonal Influenza Global Clinical Trials Review 2024 Featuring GSK, Novartis, Johnson & Johnson, Novavax, CSL, Sinovac Biotech, Moderna, and Sanofi, Among Others
Sernova Analyst Ratings
科兴生物公布高管团队增持股份进展
科兴生物1.49亿回购988.5万股 占总股本0.5%
科兴生物2023年预告亏损至多1.1亿 研发财务费增为主要原因
SINOVAC Updates on the Clinical Trial Progress of Its Anti-COVID-19 Antibody SA55 Injection
Sinovac: Given Ongoing Litigation Concerning Exchange of Shares & Rights Agreement, Unclear If or When Halt Will Lift >SVA
Sinovac Is a China-based Biopharma Co With Vaccine Portfolio Including Covid, Hep A >SVA
Sinovac: Board Also Considered Other Material Risks >SVA
Sinovac: Also Has $9.4B in Short-Term Investments, Posted 1H $14.0M in Net Income >SVA
データなし
データなし